- Home
- PRPL vs LSB Comparison
PRPL vs LSB Comparison
Compare PRPL & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- LSB
- Stock Information
- Founded
- PRPL 2010
- LSB 2002
- Country
- PRPL United States
- LSB China
- Employees
- PRPL N/A
- LSB N/A
- Industry
- PRPL Home Furnishings
- LSB
- Sector
- PRPL Consumer Discretionary
- LSB
- Exchange
- PRPL Nasdaq
- LSB NYSE
- Market Cap
- PRPL 99.7M
- LSB 72.7M
- IPO Year
- PRPL N/A
- LSB N/A
- Fundamental
- Price
- PRPL $0.92
- LSB $3.36
- Analyst Decision
- PRPL Buy
- LSB
- Analyst Count
- PRPL 5
- LSB 0
- Target Price
- PRPL $2.53
- LSB N/A
- AVG Volume (30 Days)
- PRPL 332.6K
- LSB 103.3K
- Earning Date
- PRPL 11-07-2024
- LSB 10-25-2024
- Dividend Yield
- PRPL N/A
- LSB N/A
- EPS Growth
- PRPL N/A
- LSB N/A
- EPS
- PRPL N/A
- LSB N/A
- Revenue
- PRPL $526,236,000.00
- LSB $79,415,311.00
- Revenue This Year
- PRPL N/A
- LSB $39.33
- Revenue Next Year
- PRPL $5.51
- LSB $75.61
- P/E Ratio
- PRPL N/A
- LSB N/A
- Revenue Growth
- PRPL 2.82
- LSB N/A
- 52 Week Low
- PRPL $0.55
- LSB $3.20
- 52 Week High
- PRPL $2.33
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- PRPL 39.87
- LSB 30.77
- Support Level
- PRPL $0.87
- LSB $3.20
- Resistance Level
- PRPL $0.95
- LSB $4.37
- Average True Range (ATR)
- PRPL 0.05
- LSB 0.63
- MACD
- PRPL 0.00
- LSB -0.32
- Stochastic Oscillator
- PRPL 30.48
- LSB 2.96
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.